Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
暂无分享,去创建一个
John Sampson | Allan H Friedman | A. Friedman | D. Bigner | H. Friedman | D. Reardon | J. Rich | A. Desjardins | J. Sampson | J. Vredenburgh | S. Sathornsumetee | Sridharan Gururangan | Darell D Bigner | Jeremy N Rich | David A Reardon | J. Herndon | J. Marcello | J. Quinn | S. Gururangan | Melissa Wagner | L. Bailey | James J Vredenburgh | Annick Desjardins | James E Herndon | Jennifer Marcello | Jennifer A Quinn | Sith Sathornsumetee | Melissa Wagner | Leighann Bailey | Henry S Friedman
[1] M. Westphal,et al. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] A. Grosu,et al. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. , 2006, Critical reviews in oncology/hematology.
[3] Susan Chang,et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. , 2006, Neuro-oncology.
[4] W. Welch,et al. Monoclonal Antibodies to Vascular Endothelial Growth Factor (VEGF) And the VEGF Receptor, FLT-1, Inhibit the Growth of C6 Glioma in a Mouse Xenograft , 2001, Journal of Neuro-Oncology.
[5] Kevin Camphausen,et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Brandes,et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[8] A. Brandes,et al. How effective is BCNU in recurrent glioblastoma in the modern era? , 2004, Neurology.
[9] J. Buckner,et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. , 2007, Neuro-oncology.
[10] Qiulian Wu,et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.
[11] Darell D. Bigner,et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.
[12] M. Chamberlain. Salvage Chemotherapy with CPT-11 for Recurrent Glioblastoma Multiforme , 2004, Journal of Neuro-Oncology.
[13] T. Cloughesy,et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every‐3‐week regimen , 2003, Cancer.
[14] Jan C Buckner,et al. Factors influencing survival in high-grade gliomas. , 2003, Seminars in oncology.
[15] H. Lenz,et al. Cyclooxygenase-2 inhibitors in colorectal cancer. , 2003, Seminars in oncology.
[16] A. Verma. MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .
[17] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. McLendon,et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Susan M. Chang,et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. , 2006, Neuro-oncology.
[20] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[21] H. Friedman,et al. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma , 2003, Cancer.
[22] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[23] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[24] G. Broggi,et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma , 2003, Journal of Neuro-Oncology.
[25] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[26] R. McLendon,et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma , 2005, Cancer.
[27] Rakesh K. Jain,et al. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.
[28] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[29] Lei Xu,et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.
[30] M J Gleason,et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Osoba,et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.
[32] K. Black,et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.